Press Releases

NEW BRUNSWICK, N.J., Oct. 1, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) and its Janssen Pharmaceutical Companies today announced a settlement agreement with the Ohio counties of Cuyahoga and Summit that resolves all of the counties' claims with no admi

CHICAGO, Oct. 1, 2019 /PRNewswire/ -- NOCD, a digital behavioral health company that identifies and manages people with obsessive-compulsive disorder (OCD), today announced a Series A fundraising rou

BOSTON, Oct. 1, 2019 /PRNewswire/ -- Margulies Perruzzi (MP), one of New England's most innovative architectural and interior design firms, announced the expansion

TUCSON, Ariz., Oct. 1, 2019 /PRNewswire/ -- Sabino Recovery is proud to announce and welcome Kylie Hughitt as their new Director of Outreach. Kylie brings with her over 8 years of experience in Business Development for behavioral health treatment services. She most recently joins us from The Meadows Behavioral Healthcare, where she served as Business Deve

ST. THOMAS, U.S. Virgin Islands, Oct. 1, 2019 /PRNewswire/ -- The U.S. Department's Economic Development Administration (EDA) announced on Sept. 30, that it is investing $28.6 million in the University of the Virgin Islands to support efforts to diversify and strengthen the resil

NEW YORK and SHANGHAI, Oct. 1, 2019 /PRNewswire/ -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopha

SAN DIEGO, Oct. 1, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the appointment of Kimberly Manhard to Heron's Board

SAN DIEGO, Oct. 1, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the appointment of Steve Davis to Heron's Board of Di

SAN DIEGO, Oct. 1, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced it will present data analyses evaluating the long-term effects of once-daily 40 mg INGREZZA® (valbenazine) in adults with tardive dyskinesia (TD), an involuntary movement disorder. A data analysis will also be presented on the long-term effects of INGRE

CAMP HILL, Pa., Oct. 1, 2019 /PRNewswire/ -- Trauma center accreditation status has been granted to one additional hospital in Pennsylvania starting November 1, 2019.Level IV Trauma Center Accreditation:  St. Luke's University Health Network – St. Luke's Ho